Effect of Liraglutide vs CPAP on Cardiometabolic Outcomes in Obstructive Sleep Apnea

Sponsor
St Vincent's University Hospital, Ireland
Study ID
NCT04186494
Status
Completed

Conditions

  • Sleep Apnea, Obstructive

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

  • Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml — DRUG
    GLP-1 analogue treatment in combination with advice on diet and physical exercise
  • Continuous positive airway pressure treatment — DEVICE
    Gold standard treatment for obstructive sleep apnea
  • Liraglutide and CPAP — COMBINATION_PRODUCT
    Combination of both treatments

Study Details

This is an explorative, proof-of-concept study exploring the potential therapeutic role of a Liraglutide-based weight loss regimen versus standard CPAP or the combination of both on metabolic parameters, blood pressure, endothelial function, coronary artery calcification, vascular inflammation and apnea/hypopnea index in non-diabetic patients with moderate to severe obstructive sleep apnea

Key Dates

Start date
Dec 2, 2019
Status verified
Dec 2023
Primary completion
Dec 31, 2021
Completion
Jul 31, 2022

Study Design

Enrollment
30 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Continuous positive airway pressure (CPAP)
    Standard CPAP Therapy
  • Experimental: Liraglutide-based weight loss regimen
    Once daily s.c. injections of Liraglutide, starting at a dose of 0.6 mg with weekly 0.6 mg increments to 3.0 mg in adjunct to advice on a weight-reduction diet and physical exercise
  • Experimental: Combination CPAP/Liraglutide
    Combination of both interventions

Primary Outcome Measure

Insulin resistance [ Time Frame: 6 months ]

Related Studies